David Apelian, M.D., Ph.D., has handed in his notice as EVP and chief medical officer at Achillion.
In a brief SEC filing, the biotech said he had “delivered his resignation […] effective December 28, 2017.”
The brief update said he was leaving to “pursue another professional opportunity,” though that was all she wrote on details. A retained search for a new CMO has begun, with help from Russell Reynolds Associates.
This comes three months after Janssen, the biotech unit of Johnson & Johnson, said it was ditching work with Achillion on a cocktail hep C program, citing a crowded market of innovative meds in this area, namely those from Gilead.
Achillion, with a market cap of around $400 million, was hit hard by the decision as the biotech was working with Janssen on its NS5A inhibitor, odalasvir, for this program in a potential $1 billion biobucks deal before the plug was pulled.
Some had seen Gilead or J&J as potential buyers of the company, but this has not come to fruition, and its shares have taken a hit since J&J’s decision to terminate its hep C deal.
Achillion is also now working on a midstage med, ACH-4471, in patients with untreated paroxysmal nocturnal hemoglobinuria (PNH).
By Ben Adams
Source: Fierce Biotech
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).